See Which Stocks This $23 Billion Winner Bought

Might you want to buy any of them yourself?

Jun 2, 2014 at 7:15PM

The latest 13F season is here, when many money managers issue required reports on their holdings. It can be worthwhile to pay attention, as you might get an investment idea or two by seeing what some major investors have been buying and selling.

For example, consider Lone Pine Capital, founded by Steve Mandel in 1997. Lone Pine is one of the biggest hedge fund companies, and it has reportedly outperformed the S&P 500 handily since inception. Its reportable stock portfolio totaled $23 billion in value as of March 31, 2014. According to its recently released 13F statement, Lone Pine established or added to positions in Jazz Pharmaceuticals plc (NASDAQ:JAZZ), SouFun Holdings Ltd (NYSE:SFUN), and Valeant Pharmaceuticals International (NYSE:VRX).

Jazz Pharmaceuticals has doubled in value over the past year, and with a forward P/E ratio near 14, along with double-digit growth rates, it seems like it has a lot of stock appreciation left in it. The company has a lot to offer, such as successful products on the market (narcolepsy drug Xyrem, for example), a promising pipeline, some promising acquisitions, actual profits, and solid free cash flow. It has a particular focus on orphan drugs, which tend to face little or no competition and can thus command premium prices and generate relatively reliable revenue. Based in Ireland, Jazz Pharmaceuticals even enjoys a lower tax rate. Some speculate that the company might get bought out by a bigger entity, too, as happens relatively frequently in the industry.

SouFun Holdings may not be familiar to you, but it's a China-based e-commerce specialist with a market value near $5 billion, focused on real estate, home furnishings, and home improvement, among other things. The stock has been quite volatile, more than doubling over the past year while trading at a fraction of its 52-week high. Bears don't like that China's real estate market has been accumulating excess inventory, and they weren't thrilled with SouFun's latest earnings report, which featured management tempering expectations. On the other hand, the earnings report also featured revenue growing by 33% year over year and net income surging 46%. The stock's valuation seems compelling, with a forward P/E ratio near six and a 3.3% dividend yield to boot.

Canada-based Valeant Pharmaceuticals International is a giant, with a market cap near $44 billion. It's been in the news more than usual lately after making several bids for Allergan (NYSE:AGN), maker of Botox, breast implants, eye drops, and more. Valeant has several Botox alternatives on the market and is interested in owning Botox itself. Allergan's ophthalmology products can complement Valeant's own eye-care operations, which became substantial with its $8.7 billion purchase of Bausch & Lomb last year. Some think both companies will benefit from the acquisition if it's ultimately approved, but Allergan isn't enthused, and it commissioned reports that suggest Valeant can't grow well on its own without resorting to acquisitions. Bulls see plenty of growth potential, though, and they like Valeant's business model of acquiring products rather than pouring big money into developing treatments on its own that may or may not pan out. Somewhat lost because of the Allergan story is news that Nestle has bought the U.S. and Canadian rights to Valeant skincare products for $1.4 billion.

Warren Buffett just bought nearly 9 million shares of this company
Imagine a company that rents a very specific and valuable piece of machinery for $41,000 per hour (That's almost as much as the average American makes in a year!). And Warren Buffett is so confident in this company's can't-live-without-it business model, he just loaded up on 8.8 million shares. An exclusive, brand-new Motley Fool report details this company that already has over 50% market share. Just click here to discover more about this industry-leading stock and join Buffett in his quest for a veritable landslide of profits!

Longtime Fool specialist Selena Maranjian, whom you can follow on Twitter, owns shares of Jazz Pharmaceuticals. The Motley Fool recommends Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers